News

Unveiling Amphista's Targeted Glue Technology at Leading Conferences

Unveiling Amphista's Targeted Glue Technology at Leading Conferences

Advancements in Targeted Protein Degradation

Amphista Therapeutics, a forefront leader in the field of targeted protein degradation (TPD), is set to showcase groundbreaking discoveries at major scientific conferences. Their innovative approach is focused on BRD9 degradation, utilizing their proprietary Targeted Glue® technology.

Presenting at Major Scientific Conferences

The upcoming presentations will be held at two important events: the 2nd SMR Molecular Glues meeting and the 5th Annual TPD and Induced Proximity Summit. These platforms will provide Amphista the opportunity to highlight their unique methodology for degrading BRD9, a crucial protein linked to various severe diseases.

Research Focus: BRD9 Degradation

Dr. Marta Carrara, Associate Director of Target Discovery & Validation at Amphista, will explain the extraordinary findings related to BRD9. Her presentations will clarify how the recruitment of DCAF16 through the Targeted Glue® method enables rapid and sustained degradation, making it significantly different from traditional methods like cereblon- or VHL-based PROTACs.

Innovative Conference Highlights

The public will learn about various aspects, including:

  • Details of the unique aspects of the Targeted Glue® technology.
  • The potential therapeutic applications in Acute Myeloid Leukemia and other illnesses.
  • Details about how the Eclipsys™ platform rationally designs effective protein degraders.

Key Presentation Information

Details regarding specific presentations are as follows:

2nd SMR Molecular Glues Meeting

Amphista will present at the 2nd SMR Molecular Glues meeting on the 21st of March, emphasizing the innovation behind their "Targeted Glue®" mechanism for degrading BRD9. This oral presentation is scheduled between 11:50 am and 12:30 pm GMT.

5th Annual TPD and Induced Proximity Summit

Another crucial presentation at the 5th Annual TPD and Induced Proximity Summit on the 26th of March at 9:00 am GMT will focus on the rational design of a DCAF16-recruiting BRD9 Targeted Glue®. This session is anticipated to attract significant interest, showcasing how Amphista’s unique technology is pushing the boundaries of TPD therapies.

About Amphista Therapeutics

At Amphista Therapeutics, our mission is clear: we aim to transform the landscape of treatment for severe diseases such as cancer and neurodegenerative disorders. Our approach revolves around the discovery and development of next-generation TPD medicines. Utilizing our proprietary Eclipsys™ platform, we create one-of-a-kind, bifunctional Targeted Glue® therapeutics, which offer significant advantages over existing solutions.

Innovative Therapeutics Development

We strive to deliver first- and/or best-in-class therapeutics that bring forth unmatched performance in comparison to traditional CRBN and VHL-based agents. Our commitment is strengthened by support from industry-leading investors, which includes Forbion and Novartis Venture Fund, among others.

Contact Amphista Therapeutics

If you seek more information regarding our innovative work or want to discuss potential collaborations, feel free to reach out to us:

Contacts:

Amphista Therapeutics
John Goodall
Email: info@amphista.com

ICR Healthcare
Amber Fennell, Namrata Taak, Emily Johnson
Email: amphista@icrhealthcare.com
Tel: +44 (0)20 3709 5813

Frequently Asked Questions

What technology is Amphista utilizing for BRD9 degradation?

Amphista is using its proprietary Targeted Glue® technology to efficiently degrade BRD9.

Who will present Amphista's findings?

Dr. Marta Carrara, Associate Director of Target Discovery & Validation, will deliver the presentations.

When are the presentations scheduled?

Presentations are scheduled for March 21 and March 26.

What is the significance of the DCAF16 ligase?

DCAF16 is essential for the targeted degradation process in Amphista's innovative approach.

How does Amphista's platform differ from traditional methods?

Amphista's Eclipsys™ platform allows for the design of drugs with improved properties compared to conventional therapies.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Solvang Teamsters Triumph in Labor Standoff

Updated Category News Views 9

Solvang Strikers Prevail with New Deal Staring down the barrel of a five-week standoff, the hard-nosed workers of Solvang just proved exactly what grit can get you. The City of Solvang and the steadfast members of Teamsters Local 986 wrapped up their punchy back-and-forth by clinching a contract that ups the ante on wages and job respect. For a bunch who stuck it out on...

Continue Reading
Ryan Stills: Vegan Powerlifter Defies Odds, Wins Sixth World Title

Updated Category News Views 3

Ryan Stills: A Comeback Story for the Ages Ryan Stills isn't just lifting weights; he's lifting the entire perception of what's possible after a heavy surgical setback. We're talking about a guy who stared down a hemi-shoulder replacement—a career ender for many—and came out the other side with a whole new set of gold medals. Two years ago, some might have written him...

Continue Reading
AEVEX Facing Class Action: Deadline Looms for Investors

Updated Category News Views 17

The Clock is Ticking for AVEX Investors News flash, folks: If you bought into AEVEX Corp. (NYSE: AVEX) between mid-April and early June this year, you might have a legal gold mine on your hands—or at least a shot to join a class action that could knock some dollars back into your pocket. Mark it on your calendar—October 20, 2026, is the last call to toss your hat in...

Continue Reading
U.S. Millionaire Surge: Market Waves or Mirage?

Updated Category News Views 8

Flashing Billions: Minting Millionaires at Breakneck Speed It sounds like something out of an 80s movie: every single day, over 1,200 folks in the United States become millionaires. Yep, you heard right. The UBS Global Wealth Report 2026 threw that number out, and it sure caught my attention. It's not everyday you hear about the U.S. cranking out millionaires like they're...

Continue Reading
LBT Unveils Game-Changing Cyclotron for Medical Advances

Updated Category News Views 9

Unveiling the LB-30 Cyclotron at EANM 2026 Life in nuclear medicine never stands still, and once again, Longevous Beamtech (LBT) is stirring the pot with its brand-new LB-30 series medical cyclotron. They rolled out this high-powered beast at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM 2026) in Vienna. Leaning into the 30 MeV energy...

Continue Reading
Food Trends Tease: 2027 sofi™ Awards' 75 Finalists

Updated Category News Views 6

The Specialty Food Scene Heats Up Today’s world doesn’t rest when it comes to innovation, and the same goes for the tantalizing realm of specialty foods. Hot off the press, the Specialty Food Association (SFA) just rolled out the red carpet for its 75 finalists in the 2027 sofi™ Awards. These are the future taste shapers set to take center stage at the Winter...

Continue Reading
Cruise Planners Sets AI Benchmark in Travel Innovs

Updated Category News Views 10

Unveiling the AI Arsenal of Cruise Planners Alright, listen up, folks. When you think about travel and tech, Cruise Planners ain't just dipping a toe—they're cannonballing right in, splashing everyone around with their shiny new AI tricks. Twenty-three. That's how many innovations they're flaunting this year. It's like they're running a tech marathon, and boy, are they...

Continue Reading
Navigating Braces vs. Invisalign: Key Considerations

Updated Category News Views 5

Choice Between Braces and Invisalign Isn't Straightforward When you're pondering over whether to go with braces or Invisalign, it ain't just a choice you make lightly over coffee. It's a nuanced decision that hinges on a multitude of factors as highlighted by orthodontic experts Dr. Erik Higginbottom and Dr. Kyle Higginbottom from Easton, MD, featured in HelloNation's...

Continue Reading
Clean Power Alliance's Bond Deal Secures $91M Savings

Updated Category News Views 11

CPA Triumphs Yet Again With Bond Savings I'll tell you, the Clean Power Alliance (CPA) just hit the jackpot again. We're talking a $1.4 billion energy prepayment bond deal that locks in a whopping $91.1 million in savings over the next seven years. Not bad, huh? A Closer Look at the Numbers CPA's charm—besides being the top green power supplier in the U.S.—is spinning...

Continue Reading
Baidu Faces Class Action: Investors Push Against Fraud Allegations

Updated Category News Views 11

Baidu Under Fire for Alleged Misleading Statements Here's a fresh slice of drama straight outta the corporate trenches: Baidu, Inc. (NASDAQ: BIDU) finds itself tangled in a securities fraud lawsuit that’s causing a ruckus across investor circles. Schall, Brown & Schwartz LLP, those heavyweight gladiators in shareholder rights, are calling on grieved investors to step up...

Continue Reading

Top 5 Most Recently Viewed Articles

TCL Introduces Revolutionary QD-Mini LED Televisions for Home Use

Updated Category News Views 202

TCL Revolutionizes Home Entertainment with QD-Mini LED TVs TCL CSOT has recently elevated its flagship television offerings with the new X11K and C8K QD-Mini LED TVs. These models are designed to enhance the modern home entertainment experience significantly, integrating advanced backlight technology to offer exceptional brightness and color accuracy. A New Era in Picture...

Continue Reading
Investigator Insights: Edison International Under Scrutiny

Updated Category News Views 233

Edison International Faces Legal Investigations The investigation into Edison International is gaining traction as Pomerantz LLP looks into potential securities fraud claims against the company and certain of its executives. This inquiry highlights concerns regarding possible unlawful business practices that could have significant implications for investors. Impact of...

Continue Reading
Baker Tilly and Moss Adams Join Forces to Elevate Services

Updated Category News Views 506

Transformative Merger in the Advisory and Accounting Sector In a distinctive move that represents a pivotal shift in advisory and accounting services, Baker Tilly and Moss Adams have announced their planned merger. This strategic union aims to create the sixth largest advisory CPA firm in the nation, marking a significant enhancement in industry specialization and...

Continue Reading
Tony Lama Celebrates New Styles in Men's Cowboy Boots Line

Updated Category News Views 246

Tony Lama Boots Introduces Exciting New Styles Tony Lama Boots is thrilled to announce an exciting expansion of its Men's Derby Collection, featuring six striking new 12-inch cowboy boots that perfectly blend modern sensibilities with Western traditions. Whether for work or play, these offerings elevate any wardrobe. Introducing The Plano Suede and Marco Goat Designs The...

Continue Reading
Civinity's Strategic Bond Redemption Enhances Financial Flexibility

Updated Category News Views 145

Strategic Financial Moves by Civinity Civinity has successfully exercised its right for early redemption, repurchasing €3.69 million of its private bond issue from INVL Bridge Finance ahead of schedule. The repurchase of these bonds, which were originally issued in June 2025, is a smart financial maneuver that showcases the company's commitment to optimizing its...

Continue Reading